Trial Profile
Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocitosi X (LCH) with Imatinib Mesylate.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2012
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Langerhans cell histiocytosis; Malignant thymoma; Thymic epithelial tumour
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 02 Apr 2012 New trial record